A review of the recent findings from this clinical trial examining lenalidomide, bortezomib and dexamethasone plus autologous stem cell transplant for newly diagnosed multiple myeloma.
Case: A 54-Year-Old Woman with Newly Diagnosed Multiple Myeloma (NDMM)
Clinical Presentation:
Initial Clinical Workup and Diagnosis:
Treatment:
This is a video synopsis/summary of a Case-Based Peer Perspectives featuring Douglas Sborov, MD.
The randomized phase 3 DETERMINATION trial investigated the role of autologous stem cell transplant (autoSCT) in newly diagnosed, transplant-eligible patients with multiple myeloma. In the trial, 722 patients were randomly assigned; the nontransplant arm received 3 cycles of lenalidomide, bortezomib, and dexamethasone (RVD) followed by stem cell collection and 5 more cycles of RVD. The transplant arm had 3 cycles of RVD, stem cell collection, autoSCT, and 2 more cycles of RVD. All then received indefinite lenalidomide maintenance. Primary end point was progression-free survival (PFS); secondary end points included response rates, duration of response, time to progression, overall survival, safety, and quality of life. At a median 76-month follow-up, median PFS was improved by 21 months with transplant, but no overall survival benefit was seen. These results showed that some patients may defer early transplant.
At the 2023 American Society of Hematology Annual Meeting and Exposition, an analysis highlighted PFS differences in White patients similar to the intent-to-treat population, but more similar curves in Black patients. Grade 3 or higher hematologic adverse events, overall response rates, and very good partial response rates were similar between races, but Black patients were less likely to achieve complete response or better than White patients. Important differences between these populations warrant further prospective evaluation.
Video synopsis is AI-generated and reviewed by Targeted Oncology® editorial staff.
Lower-Dose Selinexor Data Lead to Patient Selection Questions in RRMM
May 14th 2024During a Case-Based Roundtable® event, Jonathan L. Kaufman, MD, discussed which lines of therapy and at what doses would be appropriate to use selinexor in a patient with relapsed/refractory multiple myeloma in the second article of a 2-part series.
Read More
How BCMA CAR T-Cell Therapy Provides Later-Line Options in R/R Multiple Myeloma
May 10th 2024During a Case-Based Roundtable® event, Abdullah Khan, MBBS, discussed the different outcomes with idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma in both the clinic and real-world settings in the second article of a 2-part series.
Read More
Landgren on MRD as an End Point for Multiple Myeloma Trials
May 1st 2024C. Ola Landgren, MD, PhD, discussed the FDA’s unanimous ODAC vote supporting minimal residual disease as an accelerated approval end point in multiple myeloma and the implications of this vote in the myeloma research field.
Read More